These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 23336392

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G.
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of recombinant human erythropoietin responsiveness by measuring erythrocyte creatine content in haemodialysis patients.
    Hasegawa S, Nakamura S, Sugiura T, Tsuka Y, Takahashi N, Matsumura K, Okumiya T, Baden M, Shiojima I.
    BMC Nephrol; 2021 Dec 12; 22(1):413. PubMed ID: 34895154
    [Abstract] [Full Text] [Related]

  • 24. Do iron guidelines translate into good clinical practice for patients on haemodialysis?
    Morris M, Snedeker M, Reed G, Butcher B, Bradley J.
    J Ren Care; 2014 Mar 12; 40(1):49-54. PubMed ID: 24588980
    [Abstract] [Full Text] [Related]

  • 25. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
    BMJ; 1990 Mar 03; 300(6724):573-8. PubMed ID: 2108751
    [Abstract] [Full Text] [Related]

  • 26. [Pharmacotherapy quality and patient safety in haemodialysis patients treated with erythropoiesis-stimulating agents].
    de Diego Santos T, Climente Martí M, Albert Balaguer EV, Jiménez Torres NV.
    Farm Hosp; 2008 Mar 03; 32(6):315-22. PubMed ID: 19232216
    [Abstract] [Full Text] [Related]

  • 27. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Kimata N, Akiba T, Pisoni RL, Albert JM, Satayathum S, Cruz JM, Akizawa T, Andreucci VE, Young EW, Port FK.
    Nephrol Dial Transplant; 2005 May 03; 20(5):927-35. PubMed ID: 15728270
    [Abstract] [Full Text] [Related]

  • 28. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S, Kvasnicka J, Kasl M, Kozlová J, Podrouzek P, Bartûsková J, Válek A.
    Czech Med; 1990 May 03; 13(2-3):98-106. PubMed ID: 2245762
    [Abstract] [Full Text] [Related]

  • 29. Management of anaemia in United Kingdom renal units: a report from the UK Renal Registry.
    Burton C, Ansell D, Taylor H, Dunn E, Feest T.
    Nephrol Dial Transplant; 2000 Jul 03; 15(7):1022-8. PubMed ID: 10862641
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ.
    Nephrol Dial Transplant; 2004 Jan 03; 19(1):121-32. PubMed ID: 14671047
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Spanish survey on anaemia management].
    Pérez García R.
    Nefrologia; 2003 Jan 03; 23(4):300-11. PubMed ID: 14558329
    [Abstract] [Full Text] [Related]

  • 35. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S, Cropper L, Mostafa S, Turner J, Bailey G, Pugh-Clarke K.
    J Ren Care; 2008 Sep 03; 34(3):112-5. PubMed ID: 18786076
    [Abstract] [Full Text] [Related]

  • 36. [Study of various factors that could have an impact on the treatment with erythropoietin of hemodialysis anemia].
    Fernández-Gallego J, Ramos B, Ruiz A, Contreras J, Alvarez Bustos G, López de Novales E.
    Nefrologia; 2000 Sep 03; 20(2):164-70. PubMed ID: 10853198
    [Abstract] [Full Text] [Related]

  • 37. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM, Kürner B, Zech M, Krahn R, Heidland A.
    Dtsch Med Wochenschr; 1988 Jan 29; 113(4):125-9. PubMed ID: 3276487
    [Abstract] [Full Text] [Related]

  • 38. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres.
    Perrinet M, Décaudin B, Champs BB, Heran I, Urbina MA, Lemaitre V, Azar R, Odou P.
    J Clin Pharm Ther; 2010 Aug 29; 35(4):395-400. PubMed ID: 20831542
    [Abstract] [Full Text] [Related]

  • 39. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May 29; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.